ENTX stock forecast, quote, news & analysis
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins... Show more
Why Entera Bio (ENTX) Stock Is Up +13.8% in the Last 30 Days
Key Takeaways
- Entera Bio (ENTX) shares climbed roughly 13.8% over the last 30 days, rising from a September 28 close of $2.69 to $3.06 as of the October 27 close.
- The move was supported by a series of board-strengthening appointments and a steady flow of updates around the company's lead osteoporosis program, EB613.
- Entera's $275 million oversubscribed private placement, announced in late July, has extended its cash runway into 2030 and remains the dominant factor behind its elevated valuation.
- The stock remains highly volatile, trading between a low near $2.45 and a high above $3.20 during the month as investors weighed dilution risk against Phase 3 funding.
- Entera is a clinical-stage company with no meaningful revenue; its valuation is driven primarily by clinical milestones, financing, and sentiment around its oral peptide platform.
- For more detail on this ticker, explore Entera Bio's Price Targets, Earnings, and Forecast pages.
- Interested in systematic strategies? Explore Trending AI Robots to see automated approaches to trading tickers like ENTX.
Entera Bio (ENTX) Company Overview and Market Position
Entera Bio Ltd. is a clinical-stage biopharmaceutical company headquartered in Jerusalem, Israel, focused on developing orally delivered peptide and protein therapies that could replace injectable treatments. The company's proprietary N-Tab® platform is designed to enable once-daily oral tablet delivery of large-molecule drugs, targeting conditions where patient convenience and compliance have historically favored injections.
Entera's most advanced candidate, EB613 (oral PTH(1-34)), is being developed as a potential first oral, bone-building (osteoanabolic) tablet for osteoporosis. A Phase 2 study met both primary and secondary endpoints, and the company is preparing a Phase 3 registrational program. The pipeline also includes EB612 (oral PTH for hypoparathyroidism), EB618 (a GLP-1/glucagon dual agonist for obesity and metabolic disorders), and an oral GLP-2 candidate for short bowel syndrome, developed in collaboration with OPKO Health. As a pre-revenue biotech, Entera is followed closely for its clinical progress and its ability to fund late-stage development.
Entera Bio (ENTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ENTX advanced approximately 13.8%, moving from a September 28 closing price of $2.69 to $3.06 by the October 27 close. The path was not linear: shares slid to a low near $2.45 in early October before recovering through the second half of the month, finishing the period near the top of their recent range.
The broader quarterly picture is more dramatic. Entering late July, the stock traded near $2.05. A $275 million private placement announced on July 27 sent shares sharply higher, and the stock has since traded in a wide band between roughly $2.45 and $3.47. Measured from late-July levels of around $2, the stock is up approximately 49% for the quarter, even after pulling back from its late-August peak near $3.47. This reflects a re-rating driven by a transformative financing rather than new clinical data.
What Drove ENTX Stock Price in the Last 30 Days
The recent 13.8% gain has been driven primarily by corporate governance and leadership developments that reinforce confidence in Entera's Phase 3 strategy. On October 6, the company announced the appointment of Laura Hamill, a former Gilead Sciences and Amgen executive with more than 35 years of commercial leadership experience, to its board. On October 27, Entera named Dr. Juan Camilo Arjona Ferreira, Head of Research & Development and Chief Medical Officer at Organon & Co., as a director, effective December 1. His late-stage development and regulatory experience in women's health is directly relevant to EB613 and EB612.
Earlier in the month, on October 8, Entera presented additional details on the clinical study design for its planned Phase 3 registrational trial of EB613. These updates, combined with a stabilized financing position, helped offset the dilution concerns that weighed on the stock in early October and supported the recovery into late October.
What Drove ENTX Stock Performance Over the Last Quarter
The defining event of the quarter was Entera's $275 million oversubscribed private placement, announced July 27 and priced at $2.04 per share. Led by existing investor BVF Partners with participation from Longitude Capital, Vivo Capital, TCGX, RA Capital Management, Perceptive Advisors, and other healthcare-focused funds, the financing is expected to fund EB613's Phase 3 program through an anticipated New Drug Application submission and extend the company's runway into 2030.
The announcement triggered a dramatic single-day repricing, with shares spiking from around $2.05 to an intraday high above $4 before settling. In the weeks that followed, investors balanced the funding's strategic value against significant share dilution, producing the elevated-but-volatile trading range seen since. The quarter's narrative is therefore one of a de-risked balance sheet and expanded institutional backing, tempered by the ongoing execution risk inherent in a pre-revenue, Phase 3-stage biotech.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of automated trading systems from a broader library of hundreds of AI-powered bots that trade thousands of tickers. Because the platform generates such a large volume of algorithmic strategies, only the top-performing and most relevant bots are highlighted in this section, giving traders a focused view of systems that have recently demonstrated notable results. The featured robots vary considerably in strategy, holding timeframe, and performance metrics, so the section is best used as a discovery tool rather than a one-size-fits-all recommendation. For investors looking to complement fundamental research with systematic approaches, reviewing the Trending AI Robots can be a useful starting point.
ENTX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalyst for ENTX is the execution of EB613's Phase 3 registrational program, including trial initiation, enrollment progress, and any interim data readouts. Investors should also monitor the advancement of EB612 into Phase 1 development under the OPKO Health collaboration, as well as early updates on the metabolic and GLP-2 pipeline programs.
Corporate factors also matter. The board appointments announced in October take effect in December, and a special shareholder meeting scheduled for late November will address equity-plan amendments and executive retention awards tied to the July financing. Macroeconomic and sector conditions, including broader biotech financing appetite and interest-rate expectations, could influence sentiment. As a pre-revenue company with negative earnings, Entera's stock remains sensitive to financing news, dilution, and clinical outcomes, and investors should weigh these risks carefully.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ENTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ENTX turned positive on October 16, 2026. Looking at past instances where ENTX's MACD turned positive, the stock continued to rise in 51 of 53 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENTX's RSI Oscillator exited the oversold zone, 28 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ENTX as a result. In 79 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
ENTX moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ENTX crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +8.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTX advanced for three days, in 180 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ENTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 87 of 99 cases where ENTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 43 cases where ENTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ENTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ENTX's P/B Ratio (74.823) is slightly higher than the industry average of (3.498). P/E Ratio (-8.971) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1428.571) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of flu medicines
Industry Biotechnology